Physica Medica: European Journal of Medical Physics
Volume 24, Issue 4 , Pages 187-195 , December 2008

Assessment of the inhibitory effects of different radiation qualities or chemotherapeutic agents on a human melanoma cell line

  • Aleksandra M. Ristić-Fira

      Affiliations

    • Laboratory of Molecular Biology and Endocrinology, Vinča Institute of Nuclear Sciences, Mihajla Petrovica Alasa 12–14, 11001 Belgrade, Serbia
    • Corresponding Author InformationCorresponding author. Vinča Institute of Nuclear Sciences, P.O. Box 522, 11001 Belgrade, Serbia. Tel./fax: +381 11 245 5561.
    • ,
  • Ivan M. Petrović

      Affiliations

    • Laboratory of Physics, Vinča Institute of Nuclear Sciences, Mihajla Petrovica Alasa 12–14, 11001 Belgrade, Serbia
    • ,
  • Lela B. Korićanac

      Affiliations

    • Laboratory of Molecular Biology and Endocrinology, Vinča Institute of Nuclear Sciences, Mihajla Petrovica Alasa 12–14, 11001 Belgrade, Serbia
    • ,
  • Lucia M. Valastro

      Affiliations

    • Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali del Sud, Catania, Italy
    • ,
  • Giuseppe Privitera

      Affiliations

    • Instituto di Radiologia, Azienda Policlinico, Catania, Italy
    • ,
  • Giacomo Cuttone

      Affiliations

    • Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali del Sud, Catania, Italy

Received 18 December 2007 ,Revised 7 March 2008 ,Accepted 16 April 2008.

References 

  1. Courdi A, Caujolle J-P, Grange J-D, Diallo-Rosier L, Sahel J, Bacin F, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys. 1999;45:5–11
  2. Egger E, Zografos L, Schalenbourg A, Beati D, Böhringer T, Chamot L, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55(4):867–880
  3. Kinnaert E, Morandini R, Simon S, Hill HZ, Ghanem G, Van Houtte P. The degree of pigmentation modulates the radiosensitivity of human melanoma cells. Radiat Res. 2000;154:497–502
  4. Belli M, Bettega D, Calzolari P, Cera F, Cherubini R, Dalla Vecchia M, et al. Inactivation of human normal and tumour cells irradiated with low energy protons. Int J Radiat Biol. 2000;76(6):831–839
  5. Green LM, Murray DK, Tran DT, Bant AM, Kazarians G, Moyers MF, et al. Response of thyroid follicular cells to gamma irradiation compared to proton irradiation. I. Initial characterization of DNA damage, micronucleus formation, apoptosis, cell survival, and cell cycle phase redistribution. Radiat Res. 2001;155:32–42
  6. Petrović I, Ristić-Fira A, Todorović D, Valastro L, Cirrone P, Cittone G. Radiobiological analysis of human melanoma cells on the 62 MeV CATANA proton beam. Int J Radiat Biol. 2006;82(4):251–265
  7. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–3151
  8. Passagne I, Evrard A, Winum J-Y, Depeille P, Cuq P, Montero J-L, et al. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J Pharmacol Exp Ther. 2003;307(2):816–823
  9. Rünger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine or etoposide. J Invest Dermatol. 2000;114:34–39
  10. Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer. 1998;34(9):1368–1374
  11. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001;20:3–11
  12. Pauwels B, Korst AEC, De Pooter CMJ, Pattyn GGO, Lambrechts HAJ, Baay MFD, et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol. 2003;51:221–226
  13. Griffon G, Merlin J-L, Marchal C. Comparison of sulforhodamine B, tetrazolium and clonogenic assays for in vitro radiosensitivity testing in human ovarian cell lines. Anti-Cancer Drugs. 1995;6:115–123
  14. Price P, McMillan TJ. Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res. 1990;50:1392–1396
  15. Petrović I, Korićanac L, Todorović D, Ristić-Fira A, Valastro L, Privitera G, et al. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine and proton irradiation. Ann NY Acad Sci. 2007;1095:154–164
  16. Korićanac L, Petrović I, Privitera G, Cuttone G, Ristić-Fira A. HTB140 melanoma cells under proton irradiation and/or drug treatment. Russ J Phys Chem. 2007;9:1467–1470
  17. Absorbed dose determination in external beam radiotherapy: an international code of practice for dosimetry based on standards of absorbed dose to water. In: IAEA Technical Report Series No. 398. Vienna: IAEA; 2000. p. 135–150.
  18. Cirrone GAP, Cuttone G, Lojacono PA, Lo Nigro S, Mongelli V, Patti IV, et al. A 62 MeV proton beam for the treatment of ocular melanoma at Laboratori Nazionali del Sud-INFN. IEEE Trans Nucl Sci. 2004;51(3):860–865
  19. GEANT4: detector description and simulation tool. CERN Program Library; 1998.
  20. Marshall ES, Matthews JHL, Shaw JHF, Nixon J, Tumewu P, Finlay GJ, et al. Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer. 1994;30A(9):1370–1376
  21. Daşu A, Denekamp J. Inducible repair and intrinsic radiosensitivity: a complex but predictable relationship?. Radiat Res. 2000;153:279–288
  22. Rodrigez-Vincente J, Vicente-Ortega V, Canteras-Jordana M. The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. Cancer. 1998;82(3):495–502
  23. Shibuya H, Kato Y, Masuyoshi S, Isobe T, Tsuboi R, Koga M, et al. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res. 2003;13:457–464
  24. Sanada M, Takagi Y, Ito R, Sekiguchi M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair. 2004;3:413–420
  25. Raaphorst GP, Wang G, Wilkins D, Davis L, Bussey A, Stewart D, et al. Evaluation of cisplatin response in three radiation resistant and three radiation sensitive cell lines. Anticancer Res. 1994;14:1939–1942
  26. Kumala S, Niemiec P, Widel M, Hancock R, Rzeszowska-Wolny J. Apoptosis and clonogenic survival in three tumour cell lines exposed to gamma rays or chemical genotoxic agents. Cell Mol Biol Lett. 2003;8:655–665
  27. Kaina B, Mühlhausen U, Piee-Staffa A, Christmann M, Garcia Boy R, Rösch F, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther. 2004;311(2):585–593

PII: S1120-1797(08)00049-5

doi: 10.1016/j.ejmp.2008.04.002

Physica Medica: European Journal of Medical Physics
Volume 24, Issue 4 , Pages 187-195 , December 2008

Article Tools

* Image Usage & Resolution